Skip to main content

Table 2 Metabolic inhibitors sensitize SKOV3 cultures to cytotoxicity via TRAIL or cisplatin

From: Mitochondrial membrane depolarization enhances TRAIL-induced cell death in adult human granulosa tumor cells, KGN, through inhibition of BIRC5

A

TRAIL

 

Untreated

50 ng/mL

100 ng/mL

ANOVA

FCCP (μM)

Vehicle

1.00 ± 0.02a

0.90 ± 0.06a

0.93 ± 0.02a

0.1901

1.0

0.98 ± 0.04a

0.85 ± 0.04a*

0.90 ± 0.02a

0.0448

2.5

0.94 ± 0.03a

0.75 ± 0.04a**

0.79 ± 0.01b**

0.0011

5.0

0.91 ± 0.02a

0.69 ± 0.03b**

0.72 ± 0.02b**

7.16E-05

ANOVA

 

0.1335

0.0143

1.28E-06

 

B

Cisplatin

 

Untreated

1 μM

10 μM

ANOVA

FCCP (μM)

Vehicle

1.00 ± 0.01a

0.95 ± 0.07a

1.07 ± 0.04a

0.2609

1.0

0.96 ± 0.04a,b

0.85 ± 0.03a

0.99 ± 0.04a

0.1036

2.5

0.85 ± 0.00b,c

0.91 ± 0.05a

0.95 ± 0.04a

0.2008

5.0

0.80 ± 0.02c

0.78 ± 0.04a

0.88 ± 0.02b

0.1185

ANOVA

 

0.0012

0.1549

0.0384

 

C

TRAIL

 

Untreated

50 ng/mL

100 ng/mL

ANOVA

Oligomycin (μM)

Vehicle

1.0 ± 0.04a

0.97 ± 0.04a

0.95 ± 0.02a

0.5931

1.0

0.90 ± 0.01a

0.85 ± 0.01a

0.80 ± 0.01b**

0.006

2.5

0.96 ± 0.04a

0.82 ± 0.05a

0.81 ± 0.00b

0.0483

5.0

0.86 ± 0.03a

0.82 ± 0.08a

0.84 ± 0.04b

0.9093

ANOVA

 

0.0507

0.2121

0.0062

 

Cisplatin

 
  

Untreated

1 μM

10 μM

ANOVA

Oligomycin (μM)

Vehicle

1.00 ± 0.03a

0.88 ± 0.09a

0.94 ± 0.02a

0.3459

1.0

0.92 ± 0.02a

0.85 ± 0.01a*

0.84 ± 0.01b*

0.0129

2.5

0.91 ± 0.02b

0.84 ± 0.03a

0.89 ± 0.01a

0.1578

5.0

0.91 ± 0.00b

0.88 ± 0.03a

0.84 ± 0.03b

0.2232

ANOVA

 

0.0279

0.9114

0.0135

 
  1. Resistance of SKOV3 cultures to cell death inducing agents TRAIL or cisplatin was analyzed through inhibition of OXPHOS using oligomycin A and a mitochondrial membrane potential uncoupler, FCCP, using MTS viability assays. Results are presented as fold change to vehicle treated control cultures with differing letters indicating significant (p < 0.05) changes in viability with treatment of inhibitor, and asterisks indicating significant (* p < 0.05; ** p < 0.01) changes in viability with treatment of cytotoxic agent (A) Pretreatment with FCCP sensitized SKOV3 cultures to TRAIL, (B) but not cisplatin. (C) Culture viability was decreased with oligomycin A treatment prior to TRAIL, (D) as well as cisplatin